The p38 MAPK/NF-κB pathway mediates GLT-1 up-regulation during cerebral ischemic preconditioning-induced brain ischemic tolerance in rats

Brain Res Bull. 2021 Oct:175:224-233. doi: 10.1016/j.brainresbull.2021.07.029. Epub 2021 Jul 31.

Abstract

Our previous finding suggests that p38 MAPK contributes to the GLT-1 upregulation during induction of brain ischemic tolerance by cerebral ischemic preconditioning (CIP), however, the underlying mechanism is still unclear. Here, we investigated the molecular mechanisms underlying the CIP-induced GLT-1 upregulation by using Western blotting, Co-immunoprecipitation (Co-IP), electrophoretic mobility shift assay (EMSA) and thionin staining in rat hippocampus CA1 subset. We found that application of BAY11-7082 (an inhibitor of NF-κB), or dihydrokainate (an inhibitor of GLT-1), or SB203580 (an inhibitor of p38 MAPK) could attenuate the CIP-induced neuronal protection in hippocampus CA1 region of rats. Moreover, CIP caused rapid activation of NF-κB, as evidenced by nuclear translocation of NF-κB p50 protein, which led to active p50/p65 dimer formation and increased DNA binding activity. GLT-1 was also increased after CIP. Pretreatment with BAY11-7082 blocked the CIP-induced GLT-1 upregulation. The above results suggest that NF-κB participates in GLT-1 up-regulation during the induction of brain ischemic tolerance by CIP. We also found that pretreatment with SB203580 caused significant reduction of NF-κB p50 protein in nucleus, NF-κB p50/p65 dimer nuclear translocation and DNA binding activity of NF-κB. Together, we conclude that p38 MAPK/NF-κB pathway participates in the mediation of GLT-1 up-regulation during the induction of brain ischemic tolerance induced by CIP.

Keywords: Brain ischemic tolerance; Cerebral ischemic preconditioning; GLT-1; NF-κB; p38 MAPK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Ischemia / genetics*
  • CA1 Region, Hippocampal / pathology
  • Excitatory Amino Acid Transporter 2 / antagonists & inhibitors
  • Excitatory Amino Acid Transporter 2 / biosynthesis*
  • Excitatory Amino Acid Transporter 2 / genetics*
  • Imidazoles / pharmacology
  • Ischemic Preconditioning*
  • Kainic Acid / analogs & derivatives
  • Kainic Acid / pharmacology
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / genetics*
  • Male
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics*
  • NF-kappa B p50 Subunit / metabolism
  • Neuroprotection
  • Nitriles / pharmacology
  • Pyridines / pharmacology
  • Rats
  • Rats, Wistar
  • Sulfones / pharmacology
  • Transcription Factor RelA / metabolism
  • p38 Mitogen-Activated Protein Kinases

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • Excitatory Amino Acid Transporter 2
  • Imidazoles
  • NF-kappa B
  • NF-kappa B p50 Subunit
  • Nitriles
  • Pyridines
  • Slc1a2 protein, rat
  • Sulfones
  • Transcription Factor RelA
  • dihydrokainic acid
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • Kainic Acid